Characteristics of patients treated with fulvestrant as first hormonal therapy for metastatic breast cancer in a real world setting

This study examined the real-world effectiveness of fulvestrant monotherapy as first (L1) or second line (L2) treatment after metastatic breast cancer diagnosis. The study showed that first line fulvestrant in the real-world setting demonstrates comparable progression free survival benefit to clinical trial results and appeared successful in delaying chemotherapy initiation in hormone therapy naïve and late relapse patients. This finding supports the use of fulvestrant monotherapy as the first hormonal therapy in a metastatic setting.

Read More